Progress in liver disease diagnosis and treatment

ncycgdxhl · Wysłany: Wto 12:23, 08 Mar 2011

Progress in liver disease diagnosis and treatment of liver iron content in the severe fibrosis in chronic hepatitis C as a marker of alternative

Progress in diagnosis and treatment of liver iron content in the severe fibrosis in chronic hepatitis C as a marker of alternative (the original set: JournalofHepatologyApr2007; 46 (4) :587-595) BACKGROUND / AIMS: Chronic hepatitis C often found in patients with liver iron mild to moderate high levels, accompanied with the increase in fibrosis. Therefore, it was inferred iron can increase the progress of fibrosis. However, the precise role of iron remains controversial. The study to determine the role of these uncertain factors, taking into account the iron content and fibrosis of all factors. Methods: The anti-viral therapy in liver biopsy before the 586 patients included in the study. In univariate and multivariate analysis, serum ferritin and liver iron content and clinical, biological and histological variables. In the entire study group and have a clear date of infection subgroup of 380 patients by multivariate analysis assessed the effect of iron on fibrosis. Results: Only 46% of cases of its high iron albumin (in 27% of cases were found) and liver iron calm things related. 17% increase in iron content in the liver with age, and alcohol intake on men. After adjusting for variables on the ambiguity of liver iron content and fibrosis in univariate analysis between the significant correlation found does not exist. Conclusion: The results of this study show that compared with the fibrosing factors themselves more iron content in liver disease severity as a surrogate markers. In Egypt, for patients with chronic hepatitis C-related fibrosis and damage evaluation of serum biomarkers (Published in: JournalofHepatologyApr2007; 46 (4) 620-627) Background / Objective: The researchers infected with chronic hepatitis C patients evaluated in Egypt alternative to liver injury biomarkers in serum and liver biopsy are comparable. Subjects: 220 patients were in Egypt,[link widoczny dla zalogowanych], 91% infected with genotype 4 HCV,[link widoczny dla zalogowanych], in the evaluation of interferon / ribavirin treatment liver biopsy was conducted. Methods: The method derived by Ishak liver biopsy scores and biochemical experiments, platelet count and two fibrosis biomarkers (hyaluronic acid (HA) and YKL-40) were compared. Univariate logistic regression analysis identified and fibrosis, inflammatory changes and fat can be used as an independent predictor, the assessment of biomarkers to distinguish between severe fibrosis / cirrhosis and no / mild fibrosis. Results: Although age, HA,[link widoczny dla zalogowanych], YKL-40, AST increased, but platelet counts by univariate analysis, AST and HA / platelet count ratio of the reduction is correlated with the fibrosis of HA (p = 0.0001) and age (p = 0.004) after controlling for other variables are not significant. Although age and number of biological markers associated with inflammation,[link widoczny dla zalogowanych], but no such by fibrosis after controlling for a significant meaning. After controlling for fibrosis YKL-40 (p = 0.04) and aspartate aminotransferase (p = 0.05) were associated with fatty degeneration related. Conclusion: In chronic HCV Egyptians, HA young people whose low level of risk is very low fibrosis. As the number of liver biopsy may be limited,[link widoczny dla zalogowanych], so the clinical application of biomarkers is still controversial.